Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming kinase resistance in chronic myeloid leukemia.

The international journal of biochemistry & cell biology - 1 Jan 2008

Lee Francis, Fandi Abderrahim, Voi Maurizio

Abstract excerpt

Imatinib is a small-molecule inhibitor of BCR-ABL tyrosine kinase activity, with proven efficacy and tolerability. Despite imatinib's activity, the development of resistance, whether BCR-ABL dependent or independent, is a concern. BCR-ABL-dependent resistance is commonly a result of mutations in the BCR-ABL gene, which can induce a structural predisposition towards the active conformation of the protein,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Dasatinib
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, abl

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Thiazoles

Source

Identifiers

PMID: 18401881
DOI: 10.1016/j.biocel.2007.10.001

Genes

BCR
SRC
HCK
LYN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming kinase resistance in chronic myeloid leukemia.PMID 18401881Read ↗

Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemiaSemantic proximity Read ↗

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.Semantic proximity Read ↗

Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistanceSemantic proximity Read ↗

Therapeutic Targets for Overcoming BCR::ABL1 Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.Semantic proximity Read ↗

ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.Semantic proximity Read ↗

New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib ResistanceSemantic proximity Read ↗

Overcoming resistance in chronic myelogenous leukemia.Semantic proximity Read ↗

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapySemantic proximity Read ↗

Resistance in chronic myeloid leukemia: definitions and novel therapeutic agentsSemantic proximity Read ↗

Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.Semantic proximity Read ↗

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia.Semantic proximity Read ↗

Circumventing Resistance to Kinase-Inhibitor TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.